Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple

    Sponsor: ASCO

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • DCC-2618-01-001 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    Coordinator:
    RCemailImg Mirna Gonzalez
    RCphone 3052432441

    IRB: 20170452

    SDG: Neurological Cancer
    Disease Site(s):

    Esophagus,Brain and Nervous System,Other Hematopoietic,Stomach,Small Intestine,Colon,Rectum,Other Digestive Organ

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    DCC-2618-01-001: A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety,Tolerability, Efficacy, and Pharmacokinetics in Patients with AdvancedMalignancies

    Eligibility Criteria - NCT02571036 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190822 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190822

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Ovary,Prostate,Stomach,Colon,Rectum,Pancreas,Other Digestive Organ,Lung,Melanoma, skin

    Sponsor: NGM BIOPHARMACEUTICALS

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

    Eligibility Criteria - NCT04068896 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191076 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20191076

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Breast,Prostate,Bladder,Kidney,Other Urinary,Thyroid,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Soft Tissue,Melanoma, skin

    Sponsor: EISAI

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas ? INSTAL-101

    Eligibility Criteria - NCT04144140 *This information has been extracted from " www.clinicaltrials.gov"

  • 201704082 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:
    RCemailImg Carla Montoya
    RCphone 3052431139

    IRB: 20170882

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Esophagus,Stomach

    Sponsor: WUSTL

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    201704082: Ramucirumab plus irinotecan in patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma

    Eligibility Criteria - NCT03141034 *This information has been extracted from " www.clinicaltrials.gov"

  • 8951-CL-0301 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:
    RCemailImg Carla Montoya
    RCphone 3052431139

    IRB: 20180692

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Esophagus,Stomach

    Sponsor: ASTELLAS PHARMA US

    Enrolling Sites:

    Sylvester

    Title:

    8951-CL-0301:A Phase 3, Global, Multi-Center, Double-Blind, Randomized,Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2- Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    Eligibility Criteria - NCT03504397 *This information has been extracted from " www.clinicaltrials.gov"

  • 811-01 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:
    RCemailImg Carla Montoya
    RCphone 3052431139

    IRB: 20180740

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Esophagus,Stomach

    Sponsor: MERCK SHARP & DOHME

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    811: A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)

    Eligibility Criteria - NCT03615326 *This information has been extracted from " www.clinicaltrials.gov"

  • 859-00 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:
    RCemailImg Carla Montoya
    RCphone 3052431139

    IRB: 20180785

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Esophagus,Stomach

    Sponsor: MERCK SHARP & DOHME

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    MK-3475-859 :A Phase 3, Randomized, Double-Blind Clinical Study Of Pembrolizumab (MK- 3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy As First-Line Treatment In Participants with HER2 Negative, Previously Untreated, Unresectable Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-859)

    Eligibility Criteria - NCT03675737 *This information has been extracted from " www.clinicaltrials.gov"

  • IM-202 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20180968

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Stomach,Lung

    Sponsor: IAB

    Enrolling Sites:

    Sylvester

    Title:

    IM-202 : A Randomized, Open-Label, Multicenter, Phase 1b/2 Trial Evaluating The Safety And Efficacy Of Intratumorally-Administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who are Candidates ForCPI Therapy

    Eligibility Criteria - NCT03735290 *This information has been extracted from " www.clinicaltrials.gov"

  • TAB001-01 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:

    IRB: 20190182

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Esophagus,Other Endocrine System,Colon

    Sponsor: TABS

    Enrolling Sites:

    Sylvester

    Title:

    TAB001-01: tle ICMJEA Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies

    Eligibility Criteria - NCT03474640 *This information has been extracted from " www.clinicaltrials.gov"

  • 1381.2 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190219

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Bladder,Stomach,Lung

    Sponsor: BOEHRINGER INGELHEIM

    Enrolling Sites:

    Sylvester

    Title:

    1381.2: An Open Label, Phase I Dose-Finding Study Of BI 754111 In Combination With BI 754091 In Patients With Advanced Solid Cancers Followed By Expansion Cohorts At The Selected Dose Of The Combination In Patients With Non-Small Cell Lung Cancer And Other Solid Tumors

    Eligibility Criteria - NCT03156114 *This information has been extracted from " www.clinicaltrials.gov"

  • C3851001 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190114

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Cervix Uteri,Other Endocrine System,Lung

    Sponsor: PFIZER

    Enrolling Sites:

    Sylvester

    Title:

    C3851001: A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics Of Escalating Doses Of PF-06939999 (Prmt5 Inhibitor) In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Esophageal Cancer, Endometrial Cancer, CervicalCancer And Bladder Cancer

    Eligibility Criteria - NCT03854227 *This information has been extracted from " www.clinicaltrials.gov"

  • EMR100036-002 - Samuels, Michael

  • Investigator:
    Michael Samuels
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20160382

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Breast,Cervix Uteri,Stomach,Lung

    Sponsor: EMD

    Enrolling Sites:

    Sylvester

    Title:

    An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT02516813 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190673 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190673

    SDG: Breast Cancer
    Disease Site(s):

    Esophagus,Breast,Ovary,Other Female Genital,Kidney,Stomach,Colon,Lung

    Sponsor: MTEM

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"